Clinical Trials Directory

Trials / Conditions / Stage III Uterine Corpus Cancer AJCC v7

Stage III Uterine Corpus Cancer AJCC v7

11 registered clinical trials studyying Stage III Uterine Corpus Cancer AJCC v7 — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingCollecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Alliance for Clinical Trials in Oncology—
TerminatedTesting AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Canc
NCT03345784
National Cancer Institute (NCI)Phase 1
CompletedEnzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid End
NCT02684227
M.D. Anderson Cancer CenterPhase 2
WithdrawnWeb-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With
NCT03902379
Rutgers, The State University of New JerseyN/A
Active Not RecruitingmTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
NCT02208375
M.D. Anderson Cancer CenterPhase 1
Active Not RecruitingSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopi
NCT01970722
City of Hope Medical CenterPhase 1
UnknownPaclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or
NCT02065687
Gynecologic Oncology GroupPhase 2 / Phase 3
CompletedDasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT01440998
National Cancer Institute (NCI)Phase 1
CompletedEribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tum
NCT00410553
National Cancer Institute (NCI)Phase 1
UnknownFulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
NCT00006903
Gynecologic Oncology GroupPhase 2
CompletedTrastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00006089
National Cancer Institute (NCI)Phase 2